This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of Afatinib or Nintedanib may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for Afatinib and Nintedanib in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
Recent talks from Boehringer Ingelheim standalone meetings
Boehringer Ingelheim convened its newest edition of Conversations in Oncology in November 2016 in Shanghai, China. This meeting was the twelfth meeting in this series and the first Conversations in Oncology in China.
The meeting included both plenary talks as well as roundtable discussions that highlighted the key advancements in the molecular biology, testing and treatment of non-small cell lung cancer (NSCLC), focusing on targeted therapies, anti-angiogenesis agents, biomarkers, immunotherapy, and real-world treatment with patient case study discussions.
To view slides from the various presentation, simply click on your file of choice below.
Recent Advances in the Molecular Biology of Cancer Treatment
Roundtable Discussion: Molecular Testing Options
State of the Art: Recent Therapeutic Advances in Lung Cancer 2016
AE Management With EGFR TKI Therapy
Treatment Algorithm for EGFR-M+ NSCLC: Where Do the 3rd-Generation EGFR TKIs Fit In?
Roundtable Discussion on Treatment Algorithms: Sequencing for Maximal Clinical Benefit
Day 1 Summary
Antiangiogenic Therapy: Clinical Benefit for Second-Line NSCLC
Treatment Options for 2nd Line NSCLC – II: Role of TKIs in Squamous Cell Carcinoma
Immunotherapy of Lung Cancer
Day 2: Recap and Questions on Day 1 Learnings
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue